Stock IMMP IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-17 EDT 		5-day change 1st Jan Change
2.96 USD +1.37% Intraday chart for Immutep ADR -1.66% +23.33%
05-17 Capital One Initiates Immutep at Overweight Rating With $10 Price Target MT
05-15 Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer
Immutep Doses First Patient in Cancer Trial
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment
Immutep Expands Sites for Phase 1 Cancer Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. IMMP Stock
  5. News Immutep ADR
  6. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW